IGF-1R is overexpressed in poor-prognostic subtypes of multiple myeloma [18]

Leukemia

Volumn 20, Issue 1, 2006, Pages 174-176

  Chng, W J ^a   Gualberto, A ^b   Fonseca, Rafael ^a  

^a MAYO CLINIC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SYNDECAN 1;

BONE MARROW BIOPSY; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 4; COHORT ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; IMMUNOMAGNETIC SEPARATION; INFORMED CONSENT; LETTER; MAJOR CLINICAL STUDY; MALIGNANT PLASMACYTOMA; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RNA EXTRACTION;

EID: 33644976163     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2403997     Document Type: Letter

References (9)

1. Georgii-Hemming P, Wiklund HJ, Ljunggren O, Nilsson K. Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood 1996; 88: 2250-2258.
2. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004; 4: 505-518.
3. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004; 5: 221-230.
4. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy Jr J. Cyclin D dysregulation: An early and unifying pathogenic event in multiple myeloma. Blood 2005; 106: 296-303.
5. Fonseca R, Debes-Marun CS, Picken EB, Dewald GW, Bryant SC, Winkler JM et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 2003; 102: 2562-2567.
6. Tai YT, Podar K, Catley L, Tseng YH, Akiyama M, Shringarpure R et al. Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3′-kinase/AKT signaling. Cancer Res 2003; 63: 5850-5858.
7. Bataille R, Robillard N, Avet-Loiseau H, Harousseau JL, Moreau P. CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. Haematologica 2005; 90: 706-707.
8. Shaughnessy J, Jacobson J, Sawyer J, McCoy J, Fassas A, Zhan F et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: Interpretation in the context of global gene expression. Blood 2003; 101: 3849-3856.
9. Standal T, Borset M, Lenhoff S, Wisloff F, Stordal B, Sundan A et al. Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. Blood 2002; 100: 3925-3929.